Willy Roth

2.8k total citations · 2 hit papers
23 papers, 2.3k citations indexed

About

Willy Roth is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Willy Roth has authored 23 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 6 papers in Oncology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Willy Roth's work include Pharmacological Effects and Toxicity Studies (5 papers), Analytical Methods in Pharmaceuticals (5 papers) and Analytical Chemistry and Chromatography (4 papers). Willy Roth is often cited by papers focused on Pharmacological Effects and Toxicity Studies (5 papers), Analytical Methods in Pharmaceuticals (5 papers) and Analytical Chemistry and Chromatography (4 papers). Willy Roth collaborates with scholars based in Germany, France and Netherlands. Willy Roth's co-authors include Joachim Stangier, Hildegard Stähle, Karin Rathgen, Dietmar Ganßer, Thomas Ebner, Eva Ludwig-Schwellinger, Stefan Blech, K Beschke, F W Koss and R Jauch and has published in prestigious journals such as European Journal of Pharmacology, Journal of Pharmaceutical Sciences and Clinical Pharmacokinetics.

In The Last Decade

Willy Roth

23 papers receiving 2.2k citations

Hit Papers

The pharmacokinetics, pharmacodynamics and tolerability o... 2007 2026 2013 2019 2007 2007 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    2007 693 citations Joachim Stangier, Karin Rathgen et al. British Journal of Clinical Pharmacology profile →
  2. The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
    2007 549 citations Stefan Blech, Thomas Ebner et al. Drug Metabolism and Disposition profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Willy Roth Germany 17 1.4k 870 354 286 237 23 2.3k
Rebecca A. Boyd United States 21 1.4k 1.0× 800 0.9× 264 0.7× 241 0.8× 265 1.1× 34 2.4k
Ulf G. Eriksson Sweden 30 1.4k 1.0× 1.2k 1.3× 379 1.1× 399 1.4× 564 2.4× 103 3.2k
Hideo Naganuma Japan 21 1.4k 1.0× 503 0.6× 266 0.8× 140 0.5× 742 3.1× 41 2.1k
Atef Halabi Germany 25 805 0.6× 335 0.4× 221 0.6× 142 0.5× 306 1.3× 79 2.2k
C. Steven Ernest United States 22 1.4k 1.0× 311 0.4× 173 0.5× 328 1.1× 662 2.8× 41 2.1k
Nagy A. Farid United States 30 3.0k 2.2× 718 0.8× 127 0.4× 461 1.6× 1.3k 5.5× 43 3.8k
Eva Ludwig-Schwellinger Germany 8 479 0.3× 300 0.3× 367 1.0× 311 1.1× 170 0.7× 9 1.3k
Jean Combalbert France 12 778 0.6× 169 0.2× 316 0.9× 579 2.0× 309 1.3× 14 1.8k
Charles Frost United States 26 2.8k 2.0× 1.7k 2.0× 166 0.5× 250 0.9× 300 1.3× 51 3.4k
Troy C. Sarich United States 24 956 0.7× 478 0.5× 240 0.7× 410 1.4× 315 1.3× 55 2.0k

Countries citing papers authored by Willy Roth

Since Specialization
Citations

This map shows the geographic impact of Willy Roth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willy Roth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willy Roth more than expected).

Fields of papers citing papers by Willy Roth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willy Roth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willy Roth. The network helps show where Willy Roth may publish in the future.

Co-authorship network of co-authors of Willy Roth

This figure shows the co-authorship network connecting the top 25 collaborators of Willy Roth. A scholar is included among the top collaborators of Willy Roth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willy Roth. Willy Roth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stangier, Joachim, et al.. (2011). Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin. The Journal of Clinical Pharmacology. 52(2). 243–250. 46 indexed citations
2.
Yamada, Akihiro, Kazuya Maeda, Naoki Ishiguro, et al.. (2011). The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenetics and Genomics. 21(9). 523–530. 52 indexed citations
3.
Fuchs, Holger, Jean‐Paul Tillement, Saı̈k Urien, Andreas Greischel, & Willy Roth. (2009). Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. Journal of Pharmacy and Pharmacology. 61(1). 55–62. 81 indexed citations
4.
Stangier, Joachim, et al.. (2009). Coadministration of Dabigatran Etexilate and Atorvastatin. American Journal of Cardiovascular Drugs. 9(1). 59–68. 72 indexed citations
5.
Stangier, Joachim, Hildegard Stähle, Karin Rathgen, Willy Roth, & Kasra Shakeri‐Nejad. (2008). Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment. The Journal of Clinical Pharmacology. 48(12). 1411–1419. 142 indexed citations
6.
7.
Fuchs, Holger, Jean‐Paul Tillement, Saı̈k Urien, Andreas Greischel, & Willy Roth. (2008). Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. Journal of Pharmacy and Pharmacology. 61(1). 55–62. 10 indexed citations
8.
Blech, Stefan, Thomas Ebner, Eva Ludwig-Schwellinger, Joachim Stangier, & Willy Roth. (2007). The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. Drug Metabolism and Disposition. 36(2). 386–399. 549 indexed citations breakdown →
9.
Stangier, Joachim, Karin Rathgen, Hildegard Stähle, Dietmar Ganßer, & Willy Roth. (2007). The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British Journal of Clinical Pharmacology. 64(3). 292–303. 693 indexed citations breakdown →
10.
Ishiguro, Naoki, Kazuya Maeda, Wataru Kishimoto, et al.. (2006). PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS. Drug Metabolism and Disposition. 34(7). 1109–1115. 144 indexed citations
11.
Trocóniz, Iñaki F., et al.. (2006). Modelling the Anti-Migraine Effects of BIBN 4096 BS. Clinical Pharmacokinetics. 45(7). 715–728. 13 indexed citations
12.
Stopfer, Peter, Willy Roth, K. Mross, et al.. (2006). 73 POSTER Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients. European Journal of Cancer Supplements. 4(12). 26–26. 16 indexed citations
13.
Trocóniz, Iñaki F., et al.. (2004). Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists. European Journal of Pharmaceutical Sciences. 22(4). 287–295. 6 indexed citations
14.
Müller, Gabriele, et al.. (2002). Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. European Journal of Pharmaceutical Sciences. 16(3). 119–128. 16 indexed citations
15.
Stangier, Joachim, et al.. (2000). Pharmacokinetics and Safety of Intravenous and Oral Telmisartan 20 mg and 120 mg in Subjects with Hepatic Impairment Compared with Healthy Volunteers. The Journal of Clinical Pharmacology. 40(12). 1355–1364. 46 indexed citations
16.
Greischel, Andreas, et al.. (1991). Quantitation of the new hypoglycaemic agent AG-EE 388 ZW in human plasma by automated high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B Biomedical Sciences and Applications. 568(1). 246–252. 16 indexed citations
17.
18.
Verdouw, Pieter D., J. M. Hartog, Dirk J. Duncker, Willy Roth, & Pramod R. Saxena. (1986). Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. European Journal of Pharmacology. 126(1-2). 21–30. 66 indexed citations
19.
Ram, Edward, Garrett, & Willy Roth. (1983). Nonlinear Pharmacokinetics of the New Positive Inotropic Agent Sulmazole in the Dog. Journal of Pharmaceutical Sciences. 72(2). 105–116. 11 indexed citations
20.
Roth, Willy. (1983). Rapid, sensitive and fully automated high-performance liquid chromatographic assay with fluorescence detection for sulmazole and metabolites. Journal of Chromatography B Biomedical Sciences and Applications. 278(2). 347–357. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca A. Boyd Breakdown of academic impact, for papers by Ulf G. Eriksson Breakdown of academic impact, for papers by Hideo Naganuma Breakdown of academic impact, for papers by Atef Halabi Breakdown of academic impact, for papers by C. Steven Ernest Breakdown of academic impact, for papers by Nagy A. Farid Breakdown of academic impact, for papers by Eva Ludwig-Schwellinger Breakdown of academic impact, for papers by Jean Combalbert Breakdown of academic impact, for papers by Charles Frost Breakdown of academic impact, for papers by Troy C. Sarich
Rankless by CCL
2026